Christel Séguy Veyssier
Granta Design (United Kingdom)(GB)NuvOx Pharma (United States)(US)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Monoclonal and Polyclonal Antibodies Research, Radiopharmaceutical Chemistry and Applications, CAR-T cell therapy research, Glycosylation and Glycoproteins Research
Most-Cited Works
- → Oxidation of the alarmin IL-33 regulates ST2-dependent inflammation(2015)262 cited
- → At-line high throughput site-specific glycan profiling using targeted mass spectrometry(2020)10 cited
- → Abstract 2874: The tetravalent structure of FS118, a bispecific antibody targeting LAG-3 and PD-L1, is required for its novel mechanism of LAG-3 shedding(2022)2 cited
- → FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Designed for Optimal CD137 Engagement Resulting in Potent Conditional T-Cell Activity(2025)
- → The tetravalent, bispecific properties of FS118, an anti-LAG-3/PD-L1 antibody, mediate LAG-3 shedding from CD4+ and CD8+ tumor-infiltrating lymphocytes(2025)
- → Abstract 1864: FS222, a tetravalent bispecific antibody targeting CD137 and PD-L1, is designed for optimal CD137 interactions resulting in potent T cell activation without toxicity(2021)